JP2018514204A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514204A5
JP2018514204A5 JP2017554350A JP2017554350A JP2018514204A5 JP 2018514204 A5 JP2018514204 A5 JP 2018514204A5 JP 2017554350 A JP2017554350 A JP 2017554350A JP 2017554350 A JP2017554350 A JP 2017554350A JP 2018514204 A5 JP2018514204 A5 JP 2018514204A5
Authority
JP
Japan
Prior art keywords
domain
cell
car
signaling domain
intracellular signaling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017554350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514204A (ja
JP6986449B2 (ja
Filing date
Publication date
Priority claimed from GBGB1507368.7A external-priority patent/GB201507368D0/en
Application filed filed Critical
Publication of JP2018514204A publication Critical patent/JP2018514204A/ja
Publication of JP2018514204A5 publication Critical patent/JP2018514204A5/ja
Application granted granted Critical
Publication of JP6986449B2 publication Critical patent/JP6986449B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017554350A 2015-04-30 2016-04-29 ガンマデルタｔ細胞受容体（ｔｃｒ）とキメラ抗原受容体（ｃａｒ）とを発現するｔ細胞 Expired - Fee Related JP6986449B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1507368.7 2015-04-30
GBGB1507368.7A GB201507368D0 (en) 2015-04-30 2015-04-30 Cell
PCT/GB2016/051235 WO2016174461A1 (en) 2015-04-30 2016-04-29 T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)

Publications (3)

Publication Number Publication Date
JP2018514204A JP2018514204A (ja) 2018-06-07
JP2018514204A5 true JP2018514204A5 (OSRAM) 2019-06-06
JP6986449B2 JP6986449B2 (ja) 2021-12-22

Family

ID=53488907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554350A Expired - Fee Related JP6986449B2 (ja) 2015-04-30 2016-04-29 ガンマデルタｔ細胞受容体（ｔｃｒ）とキメラ抗原受容体（ｃａｒ）とを発現するｔ細胞

Country Status (16)

Country Link
US (2) US20180125890A1 (OSRAM)
EP (1) EP3288567B1 (OSRAM)
JP (1) JP6986449B2 (OSRAM)
KR (1) KR20180020140A (OSRAM)
CN (1) CN107771215A (OSRAM)
AU (1) AU2016255611B2 (OSRAM)
BR (1) BR112017023409A2 (OSRAM)
CA (1) CA2982532C (OSRAM)
EA (1) EA201792042A1 (OSRAM)
ES (1) ES3018558T3 (OSRAM)
GB (1) GB201507368D0 (OSRAM)
HK (1) HK1252235A1 (OSRAM)
IL (1) IL255186B (OSRAM)
SG (1) SG11201708402UA (OSRAM)
WO (1) WO2016174461A1 (OSRAM)
ZA (1) ZA201706923B (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN110997719B (zh) 2017-03-24 2020-12-11 莱蒂恩技术公司 用于用抗cd33免疫疗法治疗癌症的组合物和方法
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
EP3662055A1 (en) * 2017-08-02 2020-06-10 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
JP2020537640A (ja) * 2017-09-27 2020-12-24 オハイオ・ステイト・イノベーション・ファウンデーション 組織因子標的化ｃａｒ−ｎｋ及びｃａｒ−ｔ細胞療法
GB201715918D0 (en) * 2017-09-29 2017-11-15 Tc Biopharm Ltd Modified CAR-T
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
US20210309713A1 (en) * 2018-04-04 2021-10-07 Daren Biotech Limited Chimeric Antigen Receptor and Method for Treating Cancers
KR20210003810A (ko) * 2018-04-18 2021-01-12 유씨엘 비즈니스 리미티드 Treg 세포의 억제 특성을 향상시키기 위한 방법
CN108588023B (zh) * 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
CN110577932A (zh) * 2018-06-07 2019-12-17 亘喜生物科技（上海）有限公司 一种脐带血来源的嵌合抗原受体t细胞
AU2019291627A1 (en) * 2018-06-19 2020-10-08 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
JPWO2020027094A1 (ja) 2018-07-31 2021-09-16 サイアス株式会社 ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法
WO2020033464A1 (en) * 2018-08-07 2020-02-13 H. Lee Moffitt Cancer Center And Research Institute Inc. Car t-cells for the treatment of bone metastatic cancer
AU2019318021B2 (en) * 2018-08-10 2025-01-30 Kyoto University Method for producing CD3-positive cell
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
US20220111043A1 (en) * 2018-09-19 2022-04-14 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
AU2019354395A1 (en) * 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
SG11202103235PA (en) * 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
JP2022523502A (ja) 2019-01-29 2022-04-25 シャンハイ ジャオ トン ユニバーシティ キメラ抗原受容体およびその使用
WO2020172555A1 (en) * 2019-02-21 2020-08-27 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
EP3953392A1 (en) * 2019-04-12 2022-02-16 Phanes Therapeutics, Inc. Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof
US20230144237A1 (en) * 2019-04-22 2023-05-11 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
WO2020251046A1 (ja) 2019-06-14 2020-12-17 サイアス株式会社 医薬組成物
EP3986442A4 (en) * 2019-06-21 2023-10-25 Shattuck Labs, Inc. Chimeric protein expressing t-cells
GB201909283D0 (en) * 2019-06-27 2019-08-14 Cancer Research Tech Ltd Fusion proteins with enzyme activity
CN110981972B (zh) * 2019-12-25 2022-09-30 华夏源（上海）细胞基因工程股份有限公司 一种分泌双特异性抗体的嵌合抗原受体及其表达载体和应用
BR112022017419A2 (pt) * 2020-03-03 2022-10-18 Janssen Biotech Inc Células t gama-delta e usos das mesmas
EP4151660A4 (en) 2020-05-22 2024-01-17 Chongqing Precision Biotech Company Limited Fusion protein for reversing tumor microenvironment and use thereof
KR20230088333A (ko) 2020-07-17 2023-06-19 인스틸 바이오 유케이 리미티드 입양 세포 요법을 위한 표적화된 공동자극을 제공하는 수용체
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4355340A4 (en) 2021-06-16 2025-05-21 Instil Bio, Inc. RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
CN113528455A (zh) * 2021-07-19 2021-10-22 广州百暨基因科技有限公司 表达嵌合抗原受体的γδT细胞
WO2023060126A1 (en) * 2021-10-06 2023-04-13 Dana-Farber Cancer Institute, Inc. Engineered cytokine receptors for tunable adoptive cell therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360046A1 (en) 1999-01-28 2000-08-03 Lawrence S. Lamb, Jr. In vitro activated gamma delta lymphocytes
DE60140526D1 (de) 2000-04-03 2009-12-31 Therapure Biopharma Inc Herstellung von tcr gamma delta t-zellen
KR100732206B1 (ko) 2000-09-11 2007-06-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
WO2006006720A1 (ja) 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
DE602005022728D1 (de) 2004-08-19 2010-09-16 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
JPWO2008152822A1 (ja) 2007-06-15 2010-08-26 株式会社メディネット 医薬
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9833476B2 (en) * 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US10117896B2 (en) * 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
NZ711807A (en) 2013-02-06 2020-06-26 Celgene Corp Modified t lymphocytes having improved specificity
CN111139256A (zh) * 2013-02-20 2020-05-12 诺华股份有限公司 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
ES2828982T3 (es) * 2013-05-14 2021-05-28 Univ Texas Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
US10196444B2 (en) * 2013-07-29 2019-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
CA2926859A1 (en) 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
DK3071222T3 (da) * 2013-11-21 2020-11-16 Ucl Business Ltd Celle
CA3190002A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
US20170158749A1 (en) * 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
KR20170045205A (ko) 2014-07-09 2017-04-26 티씨 바이오팜 리미티드 감마 델타 t 세포 및 이의 용도
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
DK3220926T3 (da) 2014-11-17 2025-03-24 Adicet Therapeutics Inc Konstruerede gamma-delta-t-celler
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN105158466B (zh) 2015-05-05 2017-12-22 中国科学院广州生物医药与健康研究院 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法

Similar Documents

Publication Publication Date Title
JP2018514204A5 (OSRAM)
EP3475706B1 (en) Mhc-e restricted epitopes, binding molecules and related methods and uses
Lee et al. Human γδ T cell subsets and their clinical applications for cancer immunotherapy
Enqvist et al. Coordinated expression of DNAM-1 and LFA-1 in educated NK cells
JP7146397B2 (ja) 改変γδＴ細胞
WO2018005559A1 (en) Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
JP2020058380A (ja) キメラ抗原受容体及びその製造方法
BR112021002390A2 (pt) processos para gerar células modificadas e suas composições
JP2018532407A5 (OSRAM)
IL274293B1 (en) Process for generating therapeutic compositions of engineered cells
JP2017515464A5 (OSRAM)
De Bousser et al. T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy
JP2016538855A5 (OSRAM)
RU2022102250A (ru) Клетка
JP2016525873A (ja) Ｔ細胞バランス遺伝子発現、組成物およびその使用方法
JP2018517410A5 (OSRAM)
CN107206024A (zh) 改变cart细胞中的基因表达及其用途
JP2017533706A5 (OSRAM)
JP2017535292A5 (OSRAM)
JP2022541181A (ja) Ｔｃｒ遺伝子の単離方法
Cutmore et al. Current perspectives on the use of off the shelf CAR-T/NK cells for the treatment of cancer
EP4458419A3 (en) Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
US12178831B2 (en) Techniques for generating cell-based therapeutics using recombinant T cell receptor genes
Michen et al. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self
US20210290672A1 (en) Regulation of tumor-associated t cells